Among the new options is filgotinib, an oral medication that has become the most-used first-line therapy since 2021. Unlike ...

American depositary receipts of French biotechnology firm Abivax rose more than sixfold premarket after a drug candidate for bowel condition ulcerative colitis showed promise in a late-stage clinical ...

Abivax SA (NASDAQ:ABVX) stock is skyrocketing on Wednesday after the clinical-stage biotechnology company announced ...

Abivax shares surged 500% after positive phase 3 results for obefazimod in moderate-to-severe ulcerative colitis. Click here ...

Abivax has shared positive top-line results from two late-stage studies of its investigational oral miR-124 enhancer in adults with moderately to severely active ulcerative colitis (UC).

It has been a stellar week for Abivax, a French biotech developing therapeutics that harness the body’s natural regulatory ...

A majority of patients with inflammatory bowel disease (IBD) said they felt marijuana and CBD were “beneficial” and provided ...

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the ...

Shares of Paris, France-based Abivax SA (ABVX) spiked by over 400% in Wednesday's early premarket session following a ...

Researchers have found in a new study that both Clostridioides difficile infection (CDI)-hospitalized patients with end-stage ...

Gut support cells communicate with surprising precision – like brain neurons – using tiny extensions to send instructions to ...

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares ...